Focus on the heterogeneity of amyotrophic lateral sclerosis

References

• Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15:1182–94.
   PubMed Web of Science ®Google Scholar
• Belzil VV, Katzman RB, Petrucelli L. ALS and FTD: an epigenetic perspective. Acta Neuropathol. 2016;132:487–502.
   PubMed Web of Science ®Google Scholar
• Longinetti E, Mariosa D, Larsson H, Ye W, Ingre C, Almqvist C, et al. Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis. Neurology 2017;89:578–585.
   PubMed Web of Science ®Google Scholar
• Pupillo E, Bianchi E, Messina P, Chiveri L, Lunetta C, Corbo M, et al. Extrapyramidal and cognitive signs in amyotrophic lateral sclerosis: a population based cross-sectional study. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:324–30.
   PubMed Web of Science ®Google Scholar
• Mariosa D, Kamel F, Bellocco R, Ye W, Fang F. Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2015;22:1436–42.
   PubMed Web of Science ®Google Scholar
• Körner S, Kollewe K, Ilsemann J, Müller-Heine A, Dengler R, Krampfl K, et al. Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur J Neurol. 2013;20:647–54.
   PubMed Web of Science ®Google Scholar
• Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135:847–52.
   PubMed Web of Science ®Google Scholar
• Logroscino G, EURALS, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosur Psych. 2010;81:385–90.
   PubMed Web of Science ®Google Scholar
• Longinetti E, Regodón Wallin A, Samuelsson K, Press R, Zachau A, Ronnevi L-O, et al. The Swedish motor neuron disease quality registry. Amyotroph Lat Scl Frontotemporal Degener. 2018;19:528–37.
   PubMed Web of Science ®Google Scholar
• Leighton DJ, Newton J, Stephenson LJ, Colville S, Davenport R, Gorrie G, et al. Changing epidemiology of motor neurone disease in Scotland. J Neurol. 2019;266:817–25.
   PubMed Web of Science ®Google Scholar
• GBD 2016 Motor Neuron Disease Collaborators. Global, regional, and national burden of motor neuron diseases 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17:1083–97.
   PubMed Web of Science ®Google Scholar
• Zaldivar T, Gutierrez J, Lara G, Carbonara M, Logroscino G, Hardiman O. Reduced frequency of ALS in an ethnically mixed population: a population-based mortality study. Neurology 2009;72:1640–5.
   PubMed Web of Science ®Google Scholar
• Tai H, Cui L, Shen D, Li D, Cui B, Fang J. Military service and the risk of amyotrophic lateral sclerosis: a meta-analysis. J Clin Neurosci. 2017;45:337–42.
   PubMed Web of Science ®Google Scholar
• Beghi E. Are professional soccer players at higher risk for ALS? Amyotroph Lat Scl Frontotemporal Degener. 2013;14:501–6.
   PubMed Web of Science ®Google Scholar
• Chiò A, Benzi G, Dossena M, Mutani R, Mora G. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain J Neurol 2005;128:472–6.
   Google Scholar
• O’Brien M, Burke T, Heverin M, Vajda A, McLaughlin R, Gibbons J, et al. Clustering of Neuropsychiatric Disease in First-Degree and Second-Degree Relatives of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurol. 2017;74:1425–30.
   PubMed Web of Science ®Google Scholar
• Byrne S, Heverin M, Elamin M, Bede P, Lynch C, Kenna K, et al. Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: a population-based case-control cohort study of familial and sporadic amyotrophic lateral sclerosis. Ann Neurol. 2013;74:699–708.
   PubMed Web of Science ®Google Scholar
• Boison D, Aronica E. Comorbidities in Neurology: is adenosine the common link? Neuropharmacology 2015;97:18–34.
   PubMed Web of Science ®Google Scholar
• Johnston CA, Stanton BR, Turner MR, Gray R, Blunt A-M, Butt D, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 2006;253:1642–3.
   PubMed Web of Science ®Google Scholar
• Régal L, Vanopdenbosch L, Tilkin P, Van den Bosch L, Thijs V, Sciot R, et al. The G93C mutation in superoxide dismutase 1: clinicopathologic phenotype and prognosis. Arch Neurol. 2006;63:262–7.
   PubMedGoogle Scholar
• Mehta PR, Jones AR, Opie-Martin S, Shatunov A, Iacoangeli A, Al Khleifat A, et al. Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias. J Neurol Neurosurg Psychiatry. 2019;90:268–71.
   PubMed Web of Science ®Google Scholar
• Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377:162–72.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Lewis CM. Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered. 2011;71:281–8.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol. 2017;13:96–104.
   PubMed Web of Science ®Google Scholar
• Renton AE, Chiò A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17–23.
   PubMed Web of Science ®Google Scholar
• Nguyen HP, Van Broeckhoven C, van der Zee J. ALS Genes in the Genomic Era and their Implications for FTD. Trends Genet. 2018;34:404–23.
   PubMed Web of Science ®Google Scholar
• Cirulli ET, FALS Sequencing Consortium, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436–41.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13:1108–13.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617–28.
   PubMed Web of Science ®Google Scholar
• van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology 2017;89:1915–22.
   PubMed Web of Science ®Google Scholar
• Project MinE ALS Sequencing Consortium. Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. Eur J Hum Genet 2018;26:1537–46.
   PubMed Web of Science ®Google Scholar
• Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One. 2013;8:e75091.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84:130–9.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, et al. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Later Scl Frontotemporal Degener. 2019;20:538–48.
   PubMed Web of Science ®Google Scholar
• Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84:2247–57.
   PubMed Web of Science ®Google Scholar
• Lu CH, Petzold A, Topping J, Allen K, Macdonald-Wallis C, Clarke J, et al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry. 2015;86:565–73.
   PubMed Web of Science ®Google Scholar
• Zubiri I, Lombardi V, Bremang M, Mitra V, Nardo G, Adiutori R, et al. Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis. Mol Neurodegener. 2018;13:60.
   PubMed Web of Science ®Google Scholar
• Leoni E, Bremang M, Mitra V, Zubiri I, Jung S, Lu C-H, et al. Combined Tissue-Fluid Proteomics to Unravel Phenotypic Variability in Amyotrophic Lateral Sclerosis. Sci Rep. 2019;9:4478.
   PubMed Web of Science ®Google Scholar
• Filareti M, Luotti S, Pasetto L, Pignataro M, Paolella K, Messina P, et al. Decreased levels of foldase and chaperone proteins are associated with an early-onset amyotrophic lateral sclerosis. Front Mol Neurosci. 2017;10:99.
   PubMed Web of Science ®Google Scholar
• Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 1989;337:476–8.
   PubMed Web of Science ®Google Scholar
• Freskgard PO, Bergenhem N, Jonsson BH, Svensson M, Carlsson U. Isomerase and chaperone activity of prolyl isomerase in the folding of carbonic anhydrase. Science. 1992;258:466–8.
   PubMed Web of Science ®Google Scholar
• Lauranzano E, Pozzi S, Pasetto L, Stucchi R, Massignan T, Paolella K, et al. Peptidylprolyl isomerase A governs TARDBP function and assembly in heterogeneous nuclear ribonucleoprotein complexes. Brain. 2015;138:974–91.
   PubMed Web of Science ®Google Scholar
• Luotti S, Pasetto L, Porcu L, Torri V, Elezgarai SR, Pantalone S, et al. Diagnostic and prognostic values of PBMC proteins in amyotrophic lateral sclerosis. Neurobiol Dis. 2020;139:104815.
   PubMed Web of Science ®Google Scholar
• Basso M, Pozzi S, Tortarolo M, Fiordaliso F, Bisighini C, Pasetto L, et al. Mutant copper-zinc superoxide dismutase (SOD1) induces protein secretion pathway alterations and exosome release in astrocytes: implications for disease spreading and motor neuron pathology in amyotrophic lateral sclerosis. J Biol Chem. 2013;288:15699–711.
   PubMed Web of Science ®Google Scholar
• Ferrara D, Pasetto L, Bonetto V, Basso M. Role of extracellular vesicles in amyotrophic lateral sclerosis. Front Neurosci. 2018;12:574
   PubMed Web of Science ®Google Scholar
• Notarangelo M, Zucal C, Modelska A, Pesce I, Scarduelli G, Potrich C, et al. Ultrasensitive detection of cancer biomarkers by nickel-based isolation of polydisperse extracellular vesicles from blood. EBioMedicine 2019;43:114–26.
   PubMed Web of Science ®Google Scholar
• Joilin G, Leigh PN, Newbury SF, Hafezparast M. An Overview of MicroRNAs as Biomarkers of ALS. Front Neurol. 2019;10:186.
   PubMed Web of Science ®Google Scholar
• Freischmidt A, Muller K, Zondler L, Weydt P, Volk AE, Bozic AL, et al. Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain. 2014;137:2938–50.
   PubMed Web of Science ®Google Scholar
• Grolez G, Moreau C, Danel-Brunaud V, Delmaire C, Lopes R, Pradat PF, et al. The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review. BMC Neurol. 2016;16:155.
   PubMed Web of Science ®Google Scholar
• Agosta F, Spinelli EG, Filippi M. Neuroimaging in amyotrophic lateral sclerosis: current and emerging uses. Expert Rev Neurother. 2018;18:395–406.
   PubMed Web of Science ®Google Scholar
• Bede P, Bokde ALW, Byrne S, Elamin M, McLaughlin RL, Kenna K, et al. Multiparametric MRI study of ALS stratified for the C9orf72 genotype. Neurology 2013;81:361–9.
   PubMed Web of Science ®Google Scholar
• Agosta F, Ferraro PM, Riva N, Spinelli EG, Domi T, Carrera P, et al. Structural and functional brain signatures of C9orf72 in motor neuron disease. Neurobiol Aging. 2017;57:206–19.
   PubMed Web of Science ®Google Scholar
• Pradat P-F, El Mendili M-M. Neuroimaging to investigate multisystem involvement and provide biomarkers in amyotrophic lateral sclerosis. Biomed Res Int. 2014;2014:467560.
   PubMed Web of Science ®Google Scholar
• De Giorgio F, Maduro C, Fisher EMC, Acevedo-Arozena A. Transgenic and physiological mouse models give insights into different aspects of amyotrophic lateral sclerosis. Dis Model Mech 2019;12:pii:dmm037424.
   Web of Science ®Google Scholar
• Heiman-Patterson TD, Sher RB, Blankenhorn EA, Alexander G, Deitch JS, Kunst CB, et al. Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: a window of opportunity in the search for genetic modifiers. Amyotroph Later Scl. 2011;12:79–86.
   PubMed Web of Science ®Google Scholar
• Marino M, Papa S, Crippa V, Nardo G, Peviani M, Cheroni C, et al. Differences in protein quality control correlate with phenotype variability in 2 mouse models of familial amyotrophic lateral sclerosis. Neurobiol Aging. 2015;36:492–504.
   PubMed Web of Science ®Google Scholar
• Penco S, Lunetta C, Mosca L, Maestri E, Avemaria F, Tarlarini C, et al. Phenotypic heterogeneity in a SOD1 G93D Italian ALS family: an example of human model to study a complex disease. J Mol Neurosci. 2011;44:25–30.
   PubMed Web of Science ®Google Scholar
• Joyce PI, Mcgoldrick P, Saccon RA, Weber W, Fratta P, West SJ, et al. A novel SOD1-ALS mutation separates central and peripheral effects of mutant SOD1 toxicity. Hum Mol Genet. 2015;24:1883–97.
   PubMed Web of Science ®Google Scholar
• Fratta P, Sivakumar P, Humphrey J, Lo K, Ricketts T, Oliveira H, et al. Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. Embo J. 2018;37:e98684.
   PubMed Web of Science ®Google Scholar
• Arnold ES, Ling S-C, Huelga SC, Lagier-Tourenne C, Polymenidou M, Ditsworth D, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci USA. 2013;110:E736–745.
   PubMed Web of Science ®Google Scholar
• White MA, Kim E, Duffy A, Adalbert R, Phillips BU, Peters OM, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21:552–63.
   PubMed Web of Science ®Google Scholar
• Mitchell JC, McGoldrick P, Vance C, Hortobagyi T, Sreedharan J, Rogelj B, et al. Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol. 2013;125:273–88.
   PubMed Web of Science ®Google Scholar
• Devoy A, Kalmar B, Stewart M, Park H, Burke B, Noy SJ, et al. Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in ‘FUSDelta14’ knockin mice . Brain. 2017;140:2797–805.
   PubMed Web of Science ®Google Scholar
• Boeynaems S, Bogaert E, Michiels E, Gijselinck I, Sieben A, Jovičić A, et al. Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Sci Rep. 2016;6:20877
   PubMed Web of Science ®Google Scholar
• Swinnen B, Bento-Abreu A, Gendron TF, Boeynaems S, Bogaert E, Nuyts R, et al. A zebrafish model for C9orf72 ALS reveals RNA toxicity as a pathogenic mechanism. Acta Neuropathol. 2018;135:427–43.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Robberecht W, Van Den Bosch L. Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis Model Mech. 2017;10:537–49.
   PubMed Web of Science ®Google Scholar
• Bardelli D, Sassone F, Colombrita C, Volpe C, Gumina V, Peverelli S, et al. Reprogramming fibroblasts and peripheral blood cells from a C9ORF72 patient: a proof-of-principle study. J Cell Mol Med. 2020;24:4051–60.
   PubMed Web of Science ®Google Scholar
• van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, Murray ME, Heckman MG, Diehl NN, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol. 2013;12:978–88.
   PubMed Web of Science ®Google Scholar
• Nordin A, Akimoto C, Wuolikainen A, Alstermark H, Jonsson P, Birve A, et al. Extensive size variability of the GGGGCC expansion in C9orf72 in both neuronal and non-neuronal tissues in 18 patients with ALS or FTD. Hum Mol Genet. 2015;24:3133–42.
   PubMed Web of Science ®Google Scholar
• Fujimori K, Ishikawa M, Otomo A, Atsuta N, Nakamura R, Akiyama T, et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat Med. 2018;24:1579–89.
   PubMed Web of Science ®Google Scholar
• Wainger BJ, Lagier-Tourenne C. Taking on the elephant in the tissue culture room: iPSC modeling for sporadic ALS. Cell Stem Cell. 2018;23:466–7.
   PubMed Web of Science ®Google Scholar
• Grenier K, Kao J, Diamandis P. Three-dimensional modeling of human neurodegeneration: brain organoids coming of age. Mol Psychiatry. 2020;25:254–74.
   PubMed Web of Science ®Google Scholar
• Perrin S.Preclinical research: Make mouse studies work. Nature 2014;507:423–5. 10.1038/507423a
   PubMed Web of Science ®Google Scholar
• Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca M L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of AmericaProc Natl Acad Sci U S A. 2008;105:2052–7. 10.1073/pnas.0708022105 18250315
   PubMed Web of Science ®Google Scholar
• Pizzasegola C, Caron I, Daleno C, Ronchi A, Minoia C, Carrì M T, et al. Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. Amyotrophic Lateral Sclerosis. 2009;10:221–8. 10.1080/17482960902803440
   PubMed Web of Science ®Google Scholar
• Gill A, Kidd J, Vieira F, Thompson K, Perrin S.No Benefit from Chronic Lithium Dosing in a Sibling-Matched, Gender Balanced, Investigator-Blinded Trial Using a Standard Mouse Model of Familial ALS. PLoS One. 2009;4:e6489 10.1371/journal.pone.0006489
   PubMed Web of Science ®Google Scholar
• Westeneng H-J, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423–33.
   PubMed Web of Science ®Google Scholar
• van Eijk RPA, Westeneng H-J, Nikolakopoulos S, Verhagen IE, van Es MA, Eijkemans MJC, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology 2019;92:e451–e460.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius Å, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 2016;54:1655–61.
   PubMed Web of Science ®Google Scholar